Matinas Biopharma Holdings, Inc. insider trading

Every open-market purchase and sale by Matinas Biopharma Holdings, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following Matinas Biopharma Holdings, Inc.’s insiders pay?

From September 7, 2017 to August 24, 2020, 5 insiders reported 17 open-market purchases and 0 sales not made under a pre-set plan in Matinas Biopharma Holdings, Inc.

Matinas Biopharma Holdings, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	12 months after their sales	Latest report
Stern Adam K	Director	8	—	—	—	August 24, 2020
Lepore Patrick G	Director	4	—	—	—	May 18, 2020
Conrad Herbert J	Director	2	—	—	—	May 20, 2019
Ende Eric J	Director	2	—	—	—	August 22, 2019
Kucinski Keith A	Chief Financial Officer	1	—	—	—	November 26, 2019

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

← Back to Matinas Biopharma Holdings, Inc. · Funds · Politicians